PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide)

# PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide): The Pleiotropic Neuropeptide Driving Neuroscience and Stress Research

Pituitary adenylate cyclase-activating polypeptide (PACAP) stands as one of the most conserved and functionally versatile neuropeptides known to science. First isolated from ovine hypothalamic extracts in 1989 by Miyata and colleagues, PACAP was identified through its extraordinarily potent ability to stimulate cyclic adenosine monophosphate (cAMP) formation in anterior pituitary cells — an activity at least 1,000-fold greater than the structurally related vasoactive intestinal peptide (VIP) (Miyata et al., 1989). In the decades since its discovery, PACAP has emerged as a master regulator of central and peripheral stress responses, a potent neuroprotective agent, and a key signaling molecule in immunomodulation, neuroendocrine regulation, and pain research.

This guide provides a comprehensive overview of PACAP's molecular biology, receptor pharmacology, signaling cascades, and the diverse research domains where this remarkable neuropeptide is making significant contributions.

---

Molecular Structure and Isoforms

PACAP38 and PACAP27: Two Bioactive Forms

PACAP exists as two biologically active isoforms derived from the same precursor polypeptide, encoded by the ADCYAP1 gene located on human chromosome 18p11:

•PACAP38 — The predominant 38-amino acid form, C-terminally α-amidated, and the most abundant isoform in both the central nervous system (CNS) and peripheral tissues
•PACAP27 — A truncated 27-amino acid variant corresponding to the N-terminal portion of PACAP38, isolated one year after the original discovery (Miyata et al., 1990)

The full amino acid sequence of PACAP38 is:

His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys-NH₂

Evolutionary Conservation

One of the most striking features of PACAP is its extraordinary evolutionary conservation. The amino acid sequence of PACAP38 is 97% identical between mammals, and significant homology extends to non-mammalian vertebrates and even protochordates — making it one of the most conserved peptides in the entire VIP/secretin/glucagon superfamily (Vaudry et al., 2009). This remarkable conservation across more than 700 million years of evolution strongly implies critical, non-redundant biological functions.

Relationship to VIP

The N-terminal 28 amino acids of PACAP38 share 68% sequence homology with VIP, placing PACAP firmly within the VIP/secretin/growth hormone-releasing hormone (GHRH)/glucagon superfamily. Despite this structural similarity, PACAP and VIP exhibit distinct receptor selectivity profiles and functional differences, particularly at the PAC1 receptor, which is highly selective for PACAP over VIP.

---

Receptor Pharmacology: PAC1, VPAC1, and VPAC2

PACAP exerts its biological effects through three class B (secretin family) G protein-coupled receptors (GPCRs):

PAC1 Receptor (ADCYAP1R1)

The PAC1 receptor is the PACAP-selective receptor, displaying 100- to 1,000-fold higher affinity for PACAP38 and PACAP27 over VIP. PAC1 is the most extensively studied PACAP receptor and is densely expressed in:

•Brain regions: Hypothalamus, hippocampus, amygdala, cerebral cortex, cerebellum, brainstem
•Peripheral tissues: Adrenal medulla, dorsal root ganglia, trigeminal ganglia

PAC1 exhibits extensive alternative splicing, generating multiple receptor variants (null, hip, hop1, hop2, hiphop1, hiphop2) with distinct signaling properties. Each splice variant couples to adenylyl cyclase (AC) and phospholipase C (PLC) pathways with varying efficacy (Vaudry et al., 2009).

VPAC1 and VPAC2 Receptors

•VPAC1 (VIPR1) — Binds PACAP38, PACAP27, and VIP with approximately equal affinity
•VPAC2 (VIPR2) — Similarly non-selective, binding both PACAP and VIP with comparable affinity

Both VPAC receptors primarily couple to adenylyl cyclase and are widely distributed in peripheral organs including the lungs, liver, gastrointestinal tract, and immune cells.

Receptor Signaling Cascades

PACAP receptor activation triggers multiple intracellular signaling pathways (Hashimoto et al., 2002):

•cAMP/PKA pathway — The canonical signaling cascade, stimulating protein kinase A (PKA) and downstream CREB (cAMP response element-binding protein) phosphorylation
•PLC/IP3/DAG pathway — Activating protein kinase C (PKC) and calcium mobilization, primarily via PAC1 hop variants
•MAPK/ERK cascade — Promoting cell survival, differentiation, and neurite outgrowth
•PI3K/Akt pathway — Mediating anti-apoptotic and neuroprotective signaling
•β-Arrestin recruitment — Regulating receptor internalization and signaling duration; notably, PACAP38 exhibits greater potency and efficacy than PACAP27 in β-arrestin recruitment assays

This multi-pathway signaling architecture underlies PACAP's pleiotropic biological activities and explains why the peptide can simultaneously activate neuroprotective, anti-inflammatory, and neuroendocrine programs.

---

Neuroprotection and Cytoprotection Research

PACAP in Ischemic Injury Models

One of the most extensively documented research applications of PACAP is in neuroprotection following ischemic injury. Multiple independent laboratories have demonstrated that PACAP38 provides robust neuroprotection in stroke models:

•In middle cerebral artery occlusion (MCAO) models, systemic or intracerebroventricular administration of PACAP38 significantly reduced infarct volume and improved neurological outcomes, even when administered one hour after the ischemic event (Reglodi et al., 2006)
•Picomolar concentrations of PACAP38 were sufficient to reduce infarct volume in rat stroke models, demonstrating extraordinary potency (Dejda et al., 2011)
•In oxygen-glucose deprivation models, PACAP38 exhibited multimodal neuroprotection through both direct receptor-mediated effects and indirect neurotrophin-mediated pathways, including BDNF and NT-3 release and TrkB receptor activation (Lazarovici et al., 2012)

Comprehensive reviews of PACAP's role in ischemic neuroprotection have highlighted its ability to modulate multiple cell death pathways simultaneously, including apoptosis, necrosis, and autophagy (Shioda et al., 2015; Reglodi et al., 2018).

Mechanisms of Neuroprotection

PACAP's neuroprotective mechanisms operate through multiple converging pathways:

1. Anti-apoptotic signaling — Activation of Bcl-2 family members and inhibition of caspase cascades via PI3K/Akt and MAPK/ERK

2. Neurotrophin upregulation — Stimulation of BDNF, NT-3, and other neurotrophic factor expression

3. Anti-inflammatory modulation — Promotion of microglial polarization toward a pro-reparative (M2-like) phenotype and suppression of pro-inflammatory cytokine production

4. Calcium homeostasis — Regulation of intracellular calcium dynamics to prevent excitotoxic cell death

5. Mitochondrial protection — Maintenance of mitochondrial membrane potential and reduction of oxidative stress

These mechanisms parallel and complement those studied in other neuroprotective peptides such as Humanin, SS-31 (Elamipretide), and Semax, though PACAP operates through its own distinct receptor system.

Retinal Neuroprotection

PACAP has demonstrated potent retinoprotective effects in multiple research models, including optic nerve transection, retinal ischemia, excitotoxic injury, and UV light-induced damage. Studies have shown that PACAP treatment attenuates neuronal cell loss in experimental retinopathy models, with protective effects mediated primarily through PAC1 receptor activation (Fabian et al., 2012).

Neurodegenerative Disease Models

PACAP neuroprotection has been investigated across a spectrum of neurodegenerative disease models, including those relevant to Parkinson's, Alzheimer's, and Huntington's disease research. PACAP-deficient (ADCYAP1−/−) mice show accelerated age-related neurological decline, reinforcing the peptide's endogenous neuroprotective role.

---

Stress Response and Neuroendocrine Signaling

PACAP as a Master Stress Regulator

PACAP has been characterized as a "master regulator of central and peripheral stress responses" required to restore and maintain homeostasis (Mustafa, 2013). The peptide modulates the hypothalamic-pituitary-adrenal (HPA) axis at multiple levels:

•Hypothalamic CRH regulation — PACAP-containing neurons in the paraventricular nucleus (PVN) directly stimulate corticotropin-releasing hormone (CRH) expression and secretion
•Adrenal catecholamine synthesis — In the adrenal medulla, PACAP regulates catecholamine biosynthetic enzymes (tyrosine hydroxylase, dopamine β-hydroxylase, PNMT) and stimulates epinephrine release
•Autonomic nervous system modulation — PACAP fibers extensively innervate sympathetic preganglionic neurons and autonomic ganglia

PACAP, PTSD, and Fear Conditioning

A landmark 2011 study published in Nature by Ressler and colleagues demonstrated that blood levels of PACAP correlated with PTSD diagnosis and fear conditioning responses in a cohort of highly traumatized individuals. Furthermore, a single nucleotide polymorphism (SNP) in the PAC1 receptor gene (ADCYAP1R1) was associated with PTSD symptom severity in women (Ressler et al., 2011).

Subsequent research has expanded these findings:

•PAC1 receptor mRNA levels are increased in the extended amygdala following classical fear conditioning in rodent models (Ressler et al., 2012)
•Methylation of the PAC1 receptor gene is associated with PTSD symptom severity in both sexes
•Circulating PACAP levels correlate with increased amygdala-default mode network functional connectivity in individuals with PTSD
•PACAP/PAC1 signaling in the prefrontal cortex is associated with processing of traumatic stress and fear learning (Hammack et al., 2021)

These discoveries have positioned the PACAP-PAC1 system as a critical molecular node in stress-related psychiatric research, distinct from but complementary to traditional CRH and glucocorticoid-focused models.

PACAP-Deficient Mouse Phenotypes

ADCYAP1−/− (PACAP knockout) mice exhibit a constellation of behavioral and physiological phenotypes that underscore the peptide's importance in stress regulation:

•Reduced anxiety-like behavior in elevated plus maze and open field tests
•Blunted corticosterone responses to emotional stressors
•Impaired thermoregulation and increased mortality during early postnatal life
•Altered circadian behavior, including an "early bird" phenotype with premature activity onset
•Elevated locomotor activity and jumping behavior
•Impaired female fertility

---

Migraine and Pain Research

PACAP in the Trigeminovascular System

The role of PACAP in headache and pain research has generated enormous interest, particularly as a potential complementary pathway to CGRP (calcitonin gene-related peptide) in migraine pathophysiology. Key evidence includes:

•Both PACAP and PAC1 receptors are expressed in the trigeminovascular system, including trigeminal ganglia, trigeminal nucleus caudalis, and meningeal blood vessels
•Intravenous infusion of PACAP38 provokes headache and migraine-like attacks in research settings, with delayed onset patterns similar to those observed with CGRP
•PACAP27 also induces headache, implicating shared receptor mechanisms
•Plasma PACAP levels are elevated during migraine episodes and return to baseline between attacks

Anti-PACAP Therapeutic Research

The migraine field has advanced into antibody-based approaches targeting PACAP signaling (Guo et al., 2023; Rustichelli et al., 2020):

•ALD1910 (now in clinical development) — A humanized monoclonal antibody targeting PACAP38 that blocks receptor binding in a dose-dependent manner. ALD1910 recognizes a nonlinear epitope within PACAP38 and has progressed through Phase I studies
•AMG 301 — An anti-PAC1 receptor antibody that was investigated in clinical trials, targeting the receptor rather than the ligand
•Lu AG09222 — Another anti-PACAP antibody in clinical development, with early data suggesting reduction in headache intensity and duration following PACAP38 challenge

The dual neuroprotective and nociceptive roles of PACAP create a complex research landscape, as blocking PACAP for pain research must be weighed against its protective functions in other organ systems. This has been highlighted as a key consideration in the design of targeted interventions (Reglodi et al., 2018).

---

Immunomodulatory Research

Anti-Inflammatory Properties

PACAP exerts broad anti-inflammatory effects through multiple mechanisms:

•Macrophage/microglial polarization — Promoting the shift from pro-inflammatory (M1) to anti-inflammatory/reparative (M2) phenotypes
•Cytokine modulation — Suppressing TNF-α, IL-6, and IL-1β production while enhancing IL-10 secretion
•T cell regulation — Modulating T helper cell differentiation and regulatory T cell function. ADCYAP1−/− mice show enhanced susceptibility to experimental autoimmune encephalomyelitis (EAE) with impaired regulatory T cell proliferation (Tan et al., 2013)
•NF-κB pathway inhibition — Suppressing nuclear translocation of NF-κB, a master regulator of inflammatory gene expression

These immunomodulatory properties parallel those studied in other peptides on the platform, including KPV, VIP, and LL-37, though PACAP operates through its own distinct receptor triad.

---

Metabolic and Endocrine Research

Glucose Homeostasis

PACAP plays significant roles in metabolic regulation:

•PACAP stimulates insulin and glucagon secretion from pancreatic islets, functioning as an incretin-like peptide
•Both PACAP38 and PACAP27 have demonstrated effects on blood glucose regulation in experimental diabetes models
•The PACAP/PAC1 system in the hypothalamus recruits unique signaling pathways involved in energy homeostasis
•PACAP fibers innervate pancreatic islets, and PAC1 receptors are expressed on both α and β cells

Growth Hormone and Pituitary Function

As its name implies, PACAP was originally identified through its potent stimulation of adenylyl cyclase in pituitary cells. It stimulates the release of multiple pituitary hormones, including growth hormone, prolactin, ACTH, and LH, making it relevant to research involving growth hormone secretagogues and the broader GH/IGF-1 axis.

---

Research Tools and Methodological Considerations

Key Pharmacological Tools

Researchers working with the PACAP system have access to several well-characterized pharmacological tools:

Tool	Target	Function
PACAP38	PAC1, VPAC1, VPAC2	Pan-receptor agonist (PAC1-preferring)
PACAP27	PAC1, VPAC1, VPAC2	Agonist with different efficacy profile
PACAP(6-38)	PAC1	Competitive antagonist
Maxadilan	PAC1	Selective PAC1 agonist
Max.d.4 (M65)	PAC1	Selective PAC1 antagonist
VIP	VPAC1, VPAC2	Distinguishing VPAC- vs PAC1-mediated effects

Stability and Handling

PACAP peptides present specific handling challenges for research settings:

•Short biological half-life — PACAP38 has a circulating half-life of approximately 2–10 minutes due to rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV) and other peptidases
•Adsorption — PACAP peptides tend to adhere to glass and plastic surfaces; low-binding tubes and carrier proteins are recommended
•Light sensitivity — The methionine residue (Met17) is susceptible to oxidation; storage under inert atmosphere is advisable
•Reconstitution — Typically dissolved in sterile water, physiological saline, or dilute acetic acid depending on the specific application

For general guidance on peptide handling, see our guides on peptide reconstitution, solubility and solvent selection, and storage best practices.

Knockout and Transgenic Models

The availability of ADCYAP1−/− (PACAP-deficient) and ADCYAP1R1−/− (PAC1 receptor-deficient) mouse lines has been instrumental in delineating endogenous PACAP functions. Conditional and tissue-specific knockout strategies continue to refine our understanding of PACAP's roles in specific circuits and organ systems.

---

Structure-Activity Relationships and Peptide Engineering

Critical Residues for Receptor Binding

Structure-activity relationship (SAR) studies have revealed that:

•The N-terminal region (residues 1–6) of PACAP is critical for receptor activation; truncation at position 6 converts agonists to antagonists (e.g., PACAP(6-38))
•The C-terminal extension (residues 28–38) of PACAP38 enhances PAC1 receptor binding affinity and β-arrestin recruitment compared to PACAP27
•The α-helical conformation adopted by the peptide upon membrane or receptor interaction is essential for biological activity

Stabilized Analogs

The short half-life of native PACAP has driven extensive research into stabilized analogs:

•Acetylation and PEGylation strategies to reduce enzymatic degradation (similar to approaches used in peptide bioconjugation)
•D-amino acid substitutions at DPP-IV cleavage sites, analogous to the D-retro-inverso approach used with other peptides
•Nanoparticle encapsulation for sustained, localized delivery — a recent strategy showing promise in stroke research models
•Lipidation strategies to extend circulation time, drawing on principles established with GLP-1 receptor agonists

---

Current Research Frontiers

Sustained Delivery for Neuroprotection

Recent work has explored sustained local delivery of PACAP using biomaterial platforms, aiming to overcome the peptide's rapid systemic clearance. Approaches using hydrogel-based delivery systems have demonstrated improved functional outcomes in experimental stroke models by providing prolonged exposure to the peptide at the injury site while minimizing systemic side effects.

PAC1 Receptor Structural Biology

Advances in cryo-electron microscopy have begun to resolve the three-dimensional structure of the PAC1 receptor in complex with PACAP and different G protein subtypes. These structural insights are enabling rational design of novel PAC1 modulators, including both agonists for neuroprotection applications and antagonists for migraine research.

Epigenetic Regulation

The discovery that methylation of the PAC1 receptor gene (ADCYAP1R1) is associated with stress-related phenotypes has opened a new research dimension, connecting PACAP signaling to the broader field of epigenetic regulation of behavior and disease susceptibility.

Sex Differences in PACAP Signaling

A consistent finding across multiple studies is that PACAP/PAC1 effects show significant sex-dependent variation, with estrogen modulating PAC1 receptor expression and PACAP responsiveness. This has important implications for experimental design and interpretation across all PACAP research domains.

---

Summary

PACAP represents a unique convergence of neuroprotective, neuroendocrine, immunomodulatory, and nociceptive functions within a single, highly conserved peptide system. From its discovery in 1989 through the current generation of anti-PACAP antibody research and structural biology advances, the PACAP/PAC1 system continues to reveal new dimensions of biological complexity.

The peptide's pleiotropic nature — simultaneously neuroprotective and involved in pain signaling — presents both extraordinary opportunities and unique challenges for the research community. As pharmacological tools become more refined and delivery strategies more sophisticated, PACAP research is poised to yield fundamental insights into neuropeptide biology, stress physiology, and neurovascular signaling.

---

References

1. Miyata A, Arimura A, Dahl RR, et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun. 1989;164(1):567-574. PubMed

2. Miyata A, Jiang L, Dahl RD, et al. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun. 1990;170(2):643-648. PubMed

3. Vaudry D, Falluel-Morel A, Bourgault S, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev. 2009;61(3):283-357. PubMed

4. Hashimoto H, Shintani N, Baba A. PACAP and its receptors exert pleiotropic effects in the nervous system by activating multiple signaling pathways. Curr Protein Pept Sci. 2002;3(4):423-439. PubMed

5. Mustafa T. Pituitary adenylate cyclase-activating polypeptide (PACAP): a master regulator in central and peripheral stress responses. Adv Pharmacol. 2013;68:445-457. PubMed

6. Ressler KJ, Mercer KB, Bradley B, et al. Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature. 2011;470(7335):492-497. PubMed

7. Hammack SE, May V. PACAP and the PAC1 receptor in post-traumatic stress disorder. Neuropsychopharmacology. 2015;40(13):2446-2455. PubMed

8. Reglodi D, Somogyvari-Vigh A, Vigh S, et al. Neuroprotection by endogenous and exogenous PACAP following stroke. J Mol Neurosci. 2006;30(1-2):67-68. PubMed

9. Lazarovici P, Cohen G, Arien-Zakay H, et al. Multimodal neuroprotection induced by PACAP38 in oxygen-glucose deprivation and middle cerebral artery occlusion stroke models. J Mol Neurosci. 2012;48(3):526-540. PubMed

10. Dejda A, Seaborn T, Bhatt DK, et al. PACAP and a novel stable analog protect rat brain from ischemia. Peptides. 2011;32(5):1207-1216. PubMed

11. Shioda S, Nakamachi T. PACAP as a neuroprotective factor in ischemic neuronal injuries. Peptides. 2015;72:202-207. PubMed

12. Reglodi D, Vaczy A, Rubner S, et al. Protective effects of PACAP in ischemia. J Headache Pain. 2018;19(1):19. PubMed

13. Guo S, Bhatt DK, Bhatt SP, et al. Role of PACAP in migraine: An alternative to CGRP? Neurobiol Dis. 2023;176:105946. PubMed

14. Rustichelli C, et al. Targeting pituitary adenylate cyclase-activating polypeptide (PACAP) with monoclonal antibodies in migraine prevention. Expert Opin Investig Drugs. 2020;29(11):1269-1275. PubMed

15. Tan YV, Abad C, Lopez R, et al. Pituitary adenylate cyclase activating peptide deficient mice exhibit impaired thymic and extrathymic regulatory T cell proliferation during EAE. PLoS One. 2013;8(4):e61200. PubMed

---

Research Tools

Researchers sourcing this peptide for laboratory investigation can use the peptide price comparison tool to identify research-grade material from verified suppliers. For reconstitution planning, the peptide calculator provides molar mass, concentration, and dilution calculations.

This article is intended for educational and research purposes only. PACAP peptides discussed herein are research-use-only (RUO) compounds intended for laboratory investigation. This content does not constitute medical advice and should not be interpreted as guidance for any non-research application.

---

Further Reading: